No relevant relationship between glucose variability and oxidative stress in well-regulated type 2 diabetes patients

Journal of Diabetes Science and Technology

Volumn 5, Issue 1, 2011, Pages 86-92

  Siegelaar, Sarah E ^a   Barwari, Temo ^a   Kulik, Wim ^a   Hoekstra, Joost B ^a   DeVries, J Hans ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

8 isoprostanes; Glucose variability; MAGE; Oxidative stress; Type 2 diabetes

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ROSIGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL; 8 EPI PROSTAGLANDIN F2ALPHA; 8-EPI-PROSTAGLANDIN F2ALPHA; DRUG DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; PROSTAGLANDIN F2 ALPHA;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY; URINALYSIS; BLOOD; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; DIET RESTRICTION; INSTRUMENTATION; METABOLISM; METHODOLOGY; MIDDLE AGED; OBSERVER VARIATION; PHYSIOLOGY; POSTPRANDIAL STATE; STANDARD; STATISTICS; TREATMENT OUTCOME; URINE;

ADULT; AGED; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 2; DINOPROST; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; OBSERVER VARIATION; OXIDATIVE STRESS; POSTPRANDIAL PERIOD; TREATMENT OUTCOME;

EID: 79957989692     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681100500112     Document Type: Article

References (20)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-86.
2. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-12.
3. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813-20.
4. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44(8):968-83.
5. Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications. 2005;19(3):178-81.
6. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295(14):1681-7.
7. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ 2nd. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci. 1990;87(23):9383-7.
8. Roberts LJ, Morrow JD. Measurement of F2-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med. 2000;28(4):505-13.
9. Wentholt IM, Kulik W, Michels RP, Hoekstra JB, DeVries JH. Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia. 2008;51(1):183-90.
10. Proudfoot J, Barden A, Mori TA, Burke V, Croft KD, Beilin LJ, Puddey IB. Measurement of urinary F(2)-isoprostanes as markers of in vivo lipid peroxidation-A comparison of enzyme immunoassay with gas chromatography/mass spectrometry. Anal Biochem. 1999;272(2):209-15.
11. Saenger AK, Laha TJ, Edenfield MJ, Sadrzadeh SM. Quantification of urinary 8-iso-PGF2alpha using liquid chromatography-tandem mass spectrometry and association with elevated troponin levels. Clin Biochem. 2007;40(16-17):1297- 304.
12. Monnier L, Colette C, Mas E, Michel F, Cristol JP, Boegner C, Owens DR. Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia. 2010;53(3):562-71.
13. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
14. Siegelaar SE, Holleman F, Hoekstra JB, DeVries JH. Glucose variability; does it matter? Endocr Rev. 2010;31(2):171-82.
15. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes. 1970;19(9):644-55.
16. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care. 2002;25(2):275-8.
17. Basu S, Helmersson J. Factors regulating isoprostane formation in vivo. Antioxid Redox Signal. 2005;7(1-2):221-35.
18. Ceriello A, Bortolotti N, Motz E, Crescentini A, Lizzio S, Russo A, Tonutti L, Taboga C. Meal-generated oxidative stress in type 2 diabetic patients. Diabetes Care. 1998;21(9):1529-33.
19. Davi G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, Pennese E, Vitacolonna E, Bucciarelli T, Costantini F, Capani F, Patrono C. In vivo formation of 8-iso-prostaglandin f2〈 and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation. 1999;99(2):224-9.
20. Siegelaar SE, Kulik W, van Lenthe H, Mukherjee R, Hoekstra JB, DeVries JH. A randomized controlled trial comparing the effect of basal insulin and inhaled mealtime insulin on glucose variability and oxidative stress. Diabetes Obes Metab. 2009;11(7):709-14.